Cardiac Allograft Vasculopathy in Redo-transplants: Is it More or Less the Same the Second Time Around? by McCreath, Lauren et al.
9 
 
 
ORIGINAL RESEARCH  
 
Cardiac Allograft Vasculopathy in Redo-Transplants: 
Is it More or Less the Same the Second Time Around?  
Lauren McCreath, BA, 1 Michael J. Bonios, MD, PhD, 1,3 
Antigone Koliopoulou, MD, 1  Omar Wever-Pinzon, MD, 
1 Spencer Wright, BS, MBA/MHA, 1 Rami Alharethi, MD, 
1 Stephen H. McKellar, MD, 1 Greg Snow, PhD, 1 Bruce 
B. Reid, MD, 1 Katerina Skedros, BA, 1 Anya 
Ragnhildstveit, HS, 1 Stamatis N. Adamopoulos, MD, 
PhD, 3 Jose Nativi, MD, 1 Abdallah G. Kfoury, MD, 1 
Stavros G. Drakos, MD, PhD 1,2  
1 Utah Transplantation Affiliated Hospitals (UTAH) 
Cardiac Transplant Program (University of Utah 
Healthcare and School of Medicine, Intermountain 
Medical Center, Salt Lake cVeterans Affairs Medical 
Center), Salt Lake City, Utah 
2 Third Department of Cardiology, National & 
Kapodistrian University of Athens Medical School, 
Athens, Greece 
3 Onassis Cardiac Surgery Center, Athens, Greece 
 
Conflicts of Interest: None 
 
Running Title: Cardiac Allograft Vasculopathy in Redo-
Transplants 
 
Address for correspondence: Division of Cardiovascular 
Medicine, University of Utah School of Medicine & 3rd 
Department of Cardiology, National Kapodestrian University of 
Athens School of Medicine. Address: 30 North 1900 East, Room 
4A150, Salt Lake City, Utah, United States; Tel: 801-5852340, 
Fax: 801-5850701, Email: stavros.drakos@hsc.utah.edu   
 
Abstract 
 
Purpose: Cardiac allograft vasculopathy (CAV) continues to 
hinder the long-term success of heart transplant recipients.  
Redo-transplantation is currently the only definitive treatment 
for advanced CAV. We examined whether these patients are at 
similar CAV-risk with the second transplant  
Methods: Heart recipients from 1985 to 2011 at the UTAH 
program were included in the study and those with CAV as an 
indication for redo-transplantation were identified. CAV 
diagnosis was made by coronary angiography and based on the 
2010 ISHLT standardized nomenclature for CAV. Patient 
demographics, rejection history, and CAV incidence were 
analyzed.   
Results: Of the 1,169 eligible patients, 135 (11.5%) developed 
CAV post their first transplant; 78 cases within 10 years and 54 
beyond 10 years. The mean time to CAV was 6.58 years. Of the 
135 patients who developed CAV, only 21 (15.5%) ended up 
requiring a redo-transplant. Of the 21 retransplanted patients, 4 
(19.0%) developed CAV again; 2 patients within 10 years and 2 
patients beyond 10 years indicating a similar risk for CAV 
occurrence for first and redo-transplant.   
Conclusions: Our results indicate that CAV is as likely to 
develop in redo-transplants despite recent advances in 
immunosuppression and the standardized use of lipid-lowering 
agents. Although outcomes in redo-transplantation for the 
indication of CAV are favorable, efforts to better understand and 
minimize CAV are needed, especially in the face of scarce donor 
organs.  Rhythmos 2018;13(1):9-12.   
Key Words: cardiac allograft vasculopathy; redo-
transplantation 
List of Abbreviations: CAV = cardiac allograft vasculopathy; 
ISHLT = International Society for Heart and Lung 
Transplantation   
Introduction 
Cardiac transplantation is the gold standard of 
treatment for patients with end-stage heart failure. 
Analysis of International Society for Heart and Lung 
Transplantation (ISHLT) registry data show improvements 
of survival in patient’s 1-year post-transplant.1 However, 
long term success of heart transplantation continues to be 
hindered by the development of cardiac allograft 
vasculopathy (CAV). CAV is an accelerated form of 
coronary artery disease in transplanted hearts. Despite 
advances in immunosuppression and the standardized use 
of lipid-lowering agents, the incidence of CAV has seen 
little reduction in the past decade.1 Today, the standard 
method of surveillance of CAV is invasive coronary 
angiography because of its greater availability in most 
hospitals, cost effectiveness, and its applicability at any 
time in the post-transplant setting.2 In 2010, ISHLT 
developed a consensus document to standardize the 
nomenclature CAV (Fig. 1) that advocates the usage of 
coronary angiography.3 Once CAV is established in the 
allograft, treatment options are limited and outcomes are 
poor. Currently, the only definitive treatment for patients 
with advanced CAV is retransplantation. Whether these 
patients are at similar CAV-risk with the second transplant 
remains unknown and the topic of this study. Efforts to 
better understand and minimize CAV are needed, 
especially with chronic disparities between donor supply 
and the heart transplant waiting list. This study sought to 
identify the risk of CAV development in heart recipients 
undergoing a second transplant because of advanced CAV.  
Methods 
We retrospectively analyzed all patients who received 
an orthotropic heart transplant (HT) from the UTAH 
Cardiac Transplant Program (University of Utah Health, 
Intermountain Healthcare, and Salt Lake City Veterans 
Affairs Medical Center) from 1985 to 2011. An 
Institutional Review Board approved this project. Heart 
recipients who did not have CAV as an indication for redo-
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transplantation were excluded. CAV was defined as 
coronary artery narrowing in the proximal or distal 
branches diagnosed by coronary angiogram or necropsy 
report. Severity of CAV was based on the 2010 ISHLT 
standardized nomenclature for CAV.3 Classification was 
categorized as not significant (CAV0), mild (CAV1), 
moderate (CAV2), or severe (CAV3). CAV incidence was 
compared between primary and secondary allografts.  
We further gathered variables related to patient 
demographics, rejection history, donor and recipient 
cardiovascular risk factors, types of immunosuppression 
administered, medical therapy, and clinical examinations 
for primary and secondary allograft. Patient clinical follow 
ups were conducted at any UTAH Cardiac Transplant 
affiliated hospital in accordance with post-HT 
management standards.  
Data are expressed as mean ± SEM. Paired-samples 
Student t tests were used for comparisons between primary 
and secondary allograft. Independent-samples t tests were 
used for comparisons between donor characteristics. 
Significance was considered at a value of p < 0.05.  
  
Figure 1. Nomenclature for cardiac allograft vasculopathy (CAV) 
 
Results 
A total of 1,169 eligible patients received a heart 
transplant between 1985 and 2011. Figure 2 depicts their 
flow through the study. Of the 1,169 transplanted patients, 
135 patients developed CAV in their first allograft. 78 
cases developed CAV within 10 years and 54 beyond 10 
years. The mean time to CAV was 6.58 years. Of the 135 
patients who developed CAV, only 21 (15.5%) ended up 
requiring a redo-transplant. From the 21 patients 
retransplanted, 4 (19%) developed CAV again with 2 
patients within 10 years and 2 patients beyond 10 years. Of 
the 4 patients who redeveloped CAV, two patients 
developed CAV 3, one patient developed CAV 2, and one 
developed CAV 1. Patient with CAV 1 continues to be 
managed by UTAH clinicians with the remaining three 
patients passing away due to CAV recurrence. Of the 17 
patients who did not develop CAV in their secondary 
allograft, 4 of those patients died due to early mortality. 
Causes of death were acute rejection, pneumocytosis, 
cardiac and respiratory arrest, and one patient had no data.  
The incidence of CAV was statistically similar 
between primary and secondary allograft.  
Patients’ baseline characteristics along with etiologies of 
heart disease are included in Table 1. The average age was 
31.2 ± 3.9 years for the first transplant and 35.6 ± 4.1 (p= 
not significant [NS]) years for the redo-transplant. 76% of 
the cohort was male and 24% female (p=NS). The leading 
cause of heart disease was non-ischemic cardiomyopathy 
(81%). BMI was 22.3 ± 1.2 and 24.8 ± 1.4 (p=0.04) and 
hypertension prevalence was 44% and 86% (p=0.003) in 
the primary and redo-transplant, respectively. Post-
transplant clinical parameters are listed in Table 2. 
Leading treatment for developing CAV was stents with 
medical therapy (57%) (data not shown).    
 Figure 2. Patient flow chart. CAV = cardiac allograft vasculopathy  
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Donor baseline characteristics along with donor cause of 
death are listed in Table 3.  The average age was 26.6 ± 
2.7 years for the first transplant and 24.4 ± 2.9 (p=NS) 
years for the redo-transplant. 71% of the donors were male 
and 29% female (p=NS) for the primary transplant and 
76% were male and 24% (p=NS) female for secondary 
transplant. Total ischemic times were 174.8 ± 19.9 minutes 
and 192.2 ± 13.4 (p=NS) minutes for the first and redo-
transplant, respectively.   
Table 1. Patient Characteristics 
 1st Tx  2nd Tx  Significance 
p-value 
Recipient Baseline  
Characteristics 
Age 31.2 ± 3.9 35.6 ± 4.1 NS 
Male  16 (76%) N/A NS 
DM  2 (10%) 4 (19%) NS 
HTN 9 (44%) 18 (86%) 0.003 
CKD 8 (38%) 10 (48%) NS 
HLD 8 (38%) 14 (67%) NS 
Smoked 4 (19%) N/A NS 
BMI 22.3 ± 1.2 24.8 ± 1.4 0.04 
Cause of HF–no.(%) 
Ischemic 4 (19%) N/A NS 
Non-Ischemic 17 (81%) N/A NS 
All values are expressed as frequency with (%) or mean ± SEM. DM, 
diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; 
HLD, hyperlipidemia; BMI, body mass index; NS, not significant. 
 
 
Table 2. Post-Transplant Clinical Parameters 
 1st Tx  2nd Tx  Significance 
p-value 
Rejection History in 1st Year Post Tx  
2R or Greater 0.9 ± 0.2 0.5 ± 0.2 NS 
1R 5.1 ± 0.9 4.1 ± 0.8 NS 
Transplant Characteristics (yrs) 
Time from Tx to CAV  6.6 ± 0.8 9.7 ± 0.3 
(n=4) 
NS 
Time from Diagnosis 
to 2nd Tx 
1.3 ± 0.6 N/A NS 
Maintenance Immunosuppression  
CSA + AZA + PRED 12 (57%) 8 (38%) NS 
TAC + MMF + PRED 7 (33%) 8 (38%) NS 
CSA + MMF + PRED 1 (5%) 3 (14%) NS 
TAC + AZA + PRED 1 (5%) 2 (10%) NS 
Pharmacological Therapy 
Statins 16 (76%) 20 (95%) NS 
BB 7 (33%) 2 (10%) NS 
Diuretics  13 (62%) 13 (62%) NS 
ACE-I 15 (71%) 17 (81%) NS 
Inotropic Support 3 (14%) 3 (14%) NS 
All values are expressed as frequency with (%) or mean ± SEM. CSA, 
Cyclosporine; TAC, Tacrolimus; AZA, Azathioprine; MMF, 
Mycophenolate Mofetil; PRED, Prednisone; BB, beta-blocker; ACE-I, 
angiotensin-converting enzyme inhibitor; NS, not significant. 
 
Table 3. Donor Characteristics 
 1st Tx  2nd Tx  Significance 
p-value 
Donor Characteristics 
Age 26.6 ± 2.7 24.4 ± 2.9 NS 
Male  15 (71%) 16 (76%) NS 
Weight (kg) 63.3 ± 5.0 69.8 ± 4.2 NS 
Total Ischemia 
Time (min) 
174.8 ± 
19.9 
192.2 ± 
13.4 
NS 
Cause of Death 
CVA 7 (33%) 5 (23%) NS 
MVA 2 (10%) 5 (24%) NS 
Other 12 (57%) 11 (52%) NS 
All values are expressed as frequency with (%) or mean ± SEM. CVA, 
cerebrovascular accident; MVA, motor vehicle accident; NS, not 
significant. 
 
Discussion 
CAV is a leading cause of death in HT patients after 
first year post-transplant period, and it represents the 
leading cause of need for retransplantation worldwide.3,4 A 
recent registry analysis reported comparable 9-year 
survival among patients with CAV retransplanted (n=65) 
or medically managed (n=4,530): 55% versus 51%.5 
During both transplants, data were collected on patients 
who had infectious disease, particularly diseases which are 
associated with atherosclerosis in transplanted patients. No 
patients were found to have developed an infectious 
disease, such as herpes simplex virus or cytomegalovirus. 
Subgroup analysis suggested a survival benefit for 
retransplantation with associated allograft systolic 
dysfunction. The results from our retrospective study 
indicate that CAV is as likely to develop in redo-
transplants despite recent advances. Identification of risk 
factors associated with CAV development could reduce its 
incidence.2 Risk factors for CAV such as hypertension, 
hyperlipidemia, and diabetes can promote the development 
of CAV.6,7 In our study, the aforementioned risk factors 
were similar between the primary allograft and the 
secondary with the exception of hypertension being 
significantly higher during the secondary allograft. 
Hypertension often develops in HT patients because of 
necessary immunosuppressive regimens and may be an 
unavoidable risk factor.8 
Studies have showed that early recurrent rejection 
episodes correlate with progression of CAV.9,10,11 We did 
not find any significant differences in the incidences of 
allograft rejection between the first and second 
transplantation. Additionally, patients received similar 
post-transplant immunosuppression at both time points.  
Older donor age as a risk factor for CAV development 
was first noted by Gao and colleagues.12 In our study, the 
effect of older donor age was apparent in the second 
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allograft with donors over the age of 40 years old, although 
the number of older donors was limited. Older donor age 
is an important issue due to increased tendency for 
atherosclerotic changes in the older donor .13 
The pathogenesis of CAV is complex and prevention 
strategies must be initiated early with annual surveillance 
for detection of early disease.14,15,16 The usage of statin 
therapies, treatment of cardiovascular risk factors, 
prevention of acute rejection, and the introduction of 
everolimus and sirolimus have been important in the 
prevention and treatment of CAV.14  
Limitations. This study has several limitations. It was 
conducted at a single center which did not offer us a large 
sample size. Second, incidence of CAV in the primary 
allograft is low which could be due to failure of our 
database to identify everyone who developed CAV. 
Nomenclature of CAV was not standardized until 2010 so 
variability of CAV diagnosis was present in older patient 
charts. Finally, multivariable analysis was not adjusted for 
systolic dysfunction after CAV diagnosis due to the 
number of missing data points. Also potential late factors 
associated with mortality risk following the CAV 
diagnosis, such as new development of systolic 
dysfunction, rejection or additional comorbidities are not 
included. 
 
Conclusions 
CAV remains a leading cause of death after heart 
transplantation. Although outcomes in redo-
transplantation for the indication of CAV are favorable, 
efforts to better understand and minimize CAV are needed, 
especially in the face of scarce donor organs.  
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